Daewoong Pharma (069620) — Cash Flow-to-Debt Ratio
Daewoong Pharma (069620) has a Cash Flow-to-Debt Ratio of 0.05x as of September 2025, meaning its operating cash flow of ₩57.53 Billion could theoretically repay 0% of its total liabilities (₩1.26 Trillion) in one year. See Daewoong Pharma (069620) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Daewoong Pharma Cash Flow-to-Debt Ratio (2007–2024)
Historical debt coverage capacity for Daewoong Pharma across 16 annual periods. Also explore Daewoong Pharma equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Daewoong Pharma (2007–2024)
Year-by-year debt coverage analysis for Daewoong Pharma. For market capitalisation and broader financial context, see market cap of Daewoong Pharma.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.05x | ₩51.49 Billion | ₩1.05 Trillion | ▼ -71.8% |
| 2023 | 0.17x | ₩132.57 Billion | ₩762.77 Billion | ▲ +20.9% |
| 2022 | 0.14x | ₩118.21 Billion | ₩822.12 Billion | ▲ +156.3% |
| 2021 | 0.06x | ₩39.99 Billion | ₩712.77 Billion | ▼ -62.7% |
| 2020 | 0.15x | ₩100.98 Billion | ₩671.66 Billion | ▲ +59.2% |
| 2019 | 0.09x | ₩57.60 Billion | ₩609.75 Billion | ▲ +19.3% |
| 2018 | 0.08x | ₩47.50 Billion | ₩600.04 Billion | ▼ -55.7% |
| 2017 | 0.18x | ₩103.94 Billion | ₩581.99 Billion | ▲ +527.3% |
| 2016 | 0.03x | ₩15.38 Billion | ₩540.15 Billion | ▼ -71.1% |
| 2015 | 0.10x | ₩35.89 Billion | ₩364.29 Billion | ▼ -9.3% |
| 2014 | 0.11x | ₩25.95 Billion | ₩238.76 Billion | ▼ -71.7% |
| 2013 | 0.38x | ₩54.16 Billion | ₩141.05 Billion | ▼ -18.3% |
| 2012 | 0.47x | ₩45.02 Billion | ₩95.76 Billion | ▼ -18.8% |
| 2011 | 0.58x | ₩78.82 Billion | ₩136.04 Billion | ▲ +283.6% |
| 2008 | 0.15x | ₩31.33 Billion | ₩207.39 Billion | ▼ -27.9% |
| 2007 | 0.21x | ₩25.81 Billion | ₩123.24 Billion | — |